1
|
España F, Martinez M, Royo M, Vera CD, Estellés A, Aznar J, Jiménez-Cruz JF. Reference Ranges for the
Concentrations of Total and
Complexed Plasma Prostate-Specific
Antigen and Their Ratio in Patients with
Benign Prostate Hyperplasia. Eur Urol 2019. [DOI: 10.1159/000480823] [Citation(s) in RCA: 15] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
|
2
|
Estellés A, Gilabert J, Andrés C, España F, Aznar J. Plasminogen Activator Inhibitors Type 1 and Type 2 and Plasminogen Activators in Amniotic Fluid during Pregnancy. Thromb Haemost 2018. [DOI: 10.1055/s-0038-1647301] [Citation(s) in RCA: 23] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
Abstract
SummaryPlasminogen activator inhibitor activity (PAI), PAI-1 and PAI-2 antigen, and other fibrinolytic parameters were evaluated in amniotic fluid during normal pregnancy and compared with that obtained in plasma of pregnant women. The results indicate the presence of both PAI-1 and PAI-2 in amniotic fluid during normal pregnancy. In amniotic fluid, PAI-1 antigen levels increased from 194 ± 109 ng/ml (first trimester) to 640 ± 396 ng/ml (third trimester) and PAI-2 antigen levels increased from 72 ± 57 ng/ml to 173 ± 97 ng/ml. In contrast, a decrease in tissue-type plasminogen activator (t-PA) antigen level was observed during pregnancy. The PAI-1 levels in amniotic fluid were significantly higher than the PAI-1 levels in plasma of women at a similar gestational age. However, PAI activity, measured using single chain t-PA, was lower in amniotic fluid than in plasma of normal pregnant women. The PAI activity/PAI-1 antigen ratio in amniotic fluid after activation by a denaturing agent increased from 0.003 ± 0.004 to 0.059 ± 0.018. These results indicate that high levels of PAI-1 are present in amniotic fluid and suggest that this PAI-1 is present in a latent form that can be reactivated, at least partially, by a denaturing agent.
Collapse
Affiliation(s)
| | - Juan Gilabert
- Department of Obstetrics and Gynecology, Hospital “La Fe”, Valencia, Spain
| | | | | | - Justo Aznar
- Department of Clinical Pathology, Hospital “La Fe”, Valencia, Spain
| |
Collapse
|
3
|
Fernández JA, Estellés A, Gilabert J, España F, Aznar J. Functional and Immunologic Protein S in Normal Pregnant Women and in Full-Term Newborns. Thromb Haemost 2018. [DOI: 10.1055/s-0038-1646617] [Citation(s) in RCA: 34] [Impact Index Per Article: 5.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
Abstract
SummaryTotal and free protein S antigen and C4b-binding protein (C4bp) were determined by rocket immuno-electrophoresis, and functional protein S was assayed by a coagulation method, throughout pregnancy and normal puerperium and in a group of normal full-term newborns (FTN). The functional protein S assay is based on a modification of the APTT, using a mixture of test sample, protein S deficient plasma, activated protein C, phospholipids and calcium. This protein S functional assay is specific for protein S since the APTT prolongation by normal plasma was abolished by incubation of plasma with monospecific, rabbit antiprotein S IgG. The ratios of functional protein S/free protein S antigen in healthy men (n = 13) and women (n = 14) were 1.0 ± 0.13 (mean ± SD) and 1.03 ± 0.20, respectively. During pregnancy there is a decrease in functional protein S and a progressive decrease in total and free protein S antigen, with a functional/free protein S ratio of 0.75 ± 0.28 in the third trimester of pregnancy (n = 16). In early puerperium the functional protein S level was lower than the free protein S antigen level (ratio about 0.5). In the FTN group, the free protein S level was 39% and protein S activity was about 70% that of adults, with a functional/free protein S ratio of 1.84 ± 0.31. C4bp values were 23.5 ± 10.3% in the FTN group, and crossed immunoelectrophoresis showed that in this group the major protein S peak corresponded to free protein S. These results indicate that both in early puerperium and in FTN group, free protein S antigen may not be an adequate parameter for estimating of functional protein S activity. The decrease in functional protein S activity during early puerperium may be connected with the risk of developing thrombotic episodes during the postpartum period.
Collapse
Affiliation(s)
| | | | - Juan Gilabert
- The Department of Obstetrics and Gynecology, Hospital “La Fe”, Valencia, Spain
| | | | - Justo Aznar
- The Department of Clinical Pathology, Hospital “La Fe”, Valencia, Spain
| |
Collapse
|
4
|
Abstract
SummaryA family with “in vitro” increased red-cell fall out from the blood clot was studied. One member of the family (JVM) had a clinical history of hemorrhages after minor trauma or dental extractions. Routine coagulation and platelet function were normal except for the fibrinogen level which was slightly low in several members. The antigenic as well as functional evaluation of factor XIII was within normal limits. No factor XIII inhibitors were present. An increase in the clot permeability index was observed in most family members.The study of the fibrinolytic system showed an enhanced lysis of euglobulins, a normal plasminogen value, normal level of fibrin/ogen degradation products, normal fibrinolytic inhibitors, and an increase in the activity of the plasminogen activator. The activity of this activator was inhibited by an antiserum against tissue-type plasminogen activator. The t-pA inhibitor was in the normal range.It is concluded that the family studied in this paper shows familial alteration in the fibrinolytic system due to an excess of plasminogen activator immunologically related to that in human tissue.
Collapse
Affiliation(s)
- J Aznar
- The Department of Clinical Pathology, “La Fe” Hospital, Valencia, Spain
| | - A Estellés
- The Research Center, “La Fe” Hospital, Valencia, Spain
| | - V Vila
- The Research Center, “La Fe” Hospital, Valencia, Spain
| | - E Regañón
- The Research Center, “La Fe” Hospital, Valencia, Spain
| | - F España
- The Research Center, “La Fe” Hospital, Valencia, Spain
| | - P Villa
- The Department of Clinical Pathology, “La Fe” Hospital, Valencia, Spain
| |
Collapse
|
5
|
Benavent A, Estellés A, Aznar J, Martinez-Sales V, Gilabert J, Fornas E. Dysfunctional Plasminogen in Full Term Newborn - Study of Active Site of Plasmin. Thromb Haemost 2018. [DOI: 10.1055/s-0038-1661022] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
Abstract
SummaryThe functional activity and active site of plasmin in full-term newborns have been studied and compared to those in adults in order to investigate the nature of the abnormality found in newborn plasminogen descried in a previous paper.The functional activity of newborn plasminogen measured on chromogenic substrate was approximately 18% that of adult plasminogen when streptokinase was used as an activator and 12% when urokinase was used.Proteolysis of newborn plasminogen by urokinase yielding a two-chain plasmin form occurred normally, but the incorporation of diisopropylphosphorofluoridate into the light chain of newborn plasmin was approximately 23% of that observed in the light chain of adult plasmin.These observations suggest that the abnormality of full-term newborn plasminogen is located in the active site of the molecule.
Collapse
Affiliation(s)
- A Benavent
- The Research Center and Departments of Clinical Pathology and Obstetrics and Gynecology, Ciudad Sanitaria “La Fe”, Valencia, Spain
| | - A Estellés
- The Research Center and Departments of Clinical Pathology and Obstetrics and Gynecology, Ciudad Sanitaria “La Fe”, Valencia, Spain
| | - J Aznar
- The Research Center and Departments of Clinical Pathology and Obstetrics and Gynecology, Ciudad Sanitaria “La Fe”, Valencia, Spain
| | - V Martinez-Sales
- The Research Center and Departments of Clinical Pathology and Obstetrics and Gynecology, Ciudad Sanitaria “La Fe”, Valencia, Spain
| | - J Gilabert
- The Research Center and Departments of Clinical Pathology and Obstetrics and Gynecology, Ciudad Sanitaria “La Fe”, Valencia, Spain
| | - E Fornas
- The Research Center and Departments of Clinical Pathology and Obstetrics and Gynecology, Ciudad Sanitaria “La Fe”, Valencia, Spain
| |
Collapse
|
6
|
Abstract
SummaryVarious parameters of the fibrinolytic system and antigenic and functional protein C and its inhibitor were studied during normal pregnancy and in patients with preeclampsia.The fast acting tissue-type plasminogen activator inhibitor level was found to increase progressively during normal pregnancy. This increase was more evident in cases of severe preeclampsia (p<0.05). No variations were observed in protein C levels in normal pregnancies but a reduction in protein C level was noted in patients with severe preeclampsia (p<0.01). In preeclampsia, the protein C inhibitor level was higher than in normal pregnancy; it was also higher in normal pregnancy when compared to the control group.
Collapse
Affiliation(s)
- J Aznar
- The Department of Clinical Pathology, Hospital de la Seguridad Social “La Fe”, Valencia, Spain
| | - J Gilabert
- The Department of Obstetrics and Gynecology, Hospital de la Seguridad Social “La Fe”, Valencia, Spain
| | - A Estellés
- The Research Center, Hospital de la Seguridad Social “La Fe”, Valencia, Spain
| | - F España
- The Research Center, Hospital de la Seguridad Social “La Fe”, Valencia, Spain
| |
Collapse
|
7
|
Aznar J, España F, Estellés A, Royo M. Heparin Stimulation of the Inhibition of Activated Protein C and other Enzymes by Human Protein C Inhibitor - Influence of the Molecular Weight of Heparin and Ionic Strength. Thromb Haemost 2018. [DOI: 10.1055/s-0038-1650696] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
Abstract
SummaryThe ability of unfractionated (UF) heparin and low-molecular-weight heparin (LMWH) to potentiate the inhibition of fibrinolytic and coagulation factors by protein C inhibitor (PCI) was studied. Inhibition of activated protein C (APC), urokinase plasminogen activator (uPA), tissue plasminogen activator (tPA), thrombin, factor Xa (Xa), factor XIa (XIa) and plasma kallikrein (KK) by PCI was found to be dependent on the size of the polysaccharide. In general, maximal stimulation was reached with UF heparin, except in the case of KK. Differences in heparin stimulation were more pronounced for thrombin, APC, uPA, tPA and XIa, whereas inactivation of Xa by PCI was less dependent on the presence of heparin, and kallikrein showed higher potentiation with LMWH than with UF heparin. The second-order rate constants for enzyme inhibition by PCI were strongly dependent on the ionic strength, and, in general, with an ionic strength higher than 0.15 the heparin stimulation of the inhibition reactions was drastically reduced. These results may explain the large discrepancies in the literature on the effect of heparin on the stimulation of enzyme inhibition by PCI. They also show that LMWH is less efficient in stimulating the PCI inhibition of APC, uPA and tPA, which could contribute to the antithrombotic effect of these enzymes.
Collapse
Affiliation(s)
- Justo Aznar
- The Department of Clinical Pathology, “La Fe” University Hospital, Valencia, Spain
| | - Francisco España
- The Research Center, “La Fe” University Hospital, Valencia, Spain
| | - Amparo Estellés
- The Research Center, “La Fe” University Hospital, Valencia, Spain
| | - Montserrat Royo
- The Research Center, “La Fe” University Hospital, Valencia, Spain
| |
Collapse
|
8
|
Grancha S, Estellés A, Gilabert J, Chirivella M, España F, Aznar J. Decreased Expression of PAI-2 mRNA and Protein in Pregnancies Complicated with Intrauterine Fetal Growth Retardation. Thromb Haemost 2018. [DOI: 10.1055/s-0038-1650657] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
Abstract
SummaryAn increase in plasma plasminogen activator inhibitors (PAIs), fundamentally PAI type 2 (PAI-2), has been described in normal pregnancy probably because the placenta is the main source of the high plasma levels of this protein. Although we have previously described plasmatic alterations of these inhibitors in pregnancies complicated with intrauterine fetal growth retardation (IUGR), no reports have been published about placental PAI-2 mRNA expression. In the present study, the placental PAI-2 expression determined in pregnancies complicated with IUGR and in severe preeclamptic patients was compared with that of normal pregnancies in order to identify the placental cell types expressing PAI-2 and to determine whether the production of PAI-2 is altered in placentas from IUGR. In situ hybridization analyses show that the syncytiotrophoblasts are the cells with the greatest PAI-2 expression in placenta. We report that the significant decrease in plasma and placental PAI-2 levels in IUGR groups is fundamentally due to a diminished expression of PAI-2 mRNA in placenta.
Collapse
Affiliation(s)
- Salvador Grancha
- The Research Center, La Fe Universitary Hospital, Valencia, Spain
| | - Amparo Estellés
- The Research Center, La Fe Universitary Hospital, Valencia, Spain
| | - Juan Gilabert
- Maternal Center, La Fe Universitary Hospital, Valencia, Spain
| | | | - Francisco España
- The Research Center, La Fe Universitary Hospital, Valencia, Spain
| | - Justo Aznar
- Clinical Pathology, La Fe Universitary Hospital, Valencia, Spain
| |
Collapse
|
9
|
España F, Zuazu I, Vicente V, Estellés A, Marco P, Aznar J. Quantification of Circulating Activated Protein C in Human Plasma by Immunoassays - Enzyme Levels are Proportional to Total Protein C Levels. Thromb Haemost 2018. [DOI: 10.1055/s-0038-1650221] [Citation(s) in RCA: 28] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
Abstract
SummaryWe have developed a simple assay that measures the circulating activated protein C (APC) in plasma. The assay requires collection of duplicate blood samples, one in citrate plus heparin and the other in citrate plus inhibitors of the enzyme. In the heparin tube, APC reacts completely and irreversibly with its major plasma inhibitors, protein C inhibitor (PCI) and α1-antitrypsin (α1AT), and the complexes formed are measured by ELISAs. The amount of circulating APC is calculated from the difference between the total amount of complexed APC (sample in citrate plus heparin) and the amount of APC complexed in vivo (sample in citrate plus inhibitor). Over 95% of the APC added to blood collected with heparin was recovered in the assay. The assay can easily be performed in four hours, and had a detection limit of 0.1 ng/ml APC. The mean APC level in 18 protein C heterozygous members from seven kindreds was significantly lower (0.6 ± 0.3 ng/ml) than in 20 healthy controls (1.1 ± 0.3 ng/ml) (p <0.001), whereas the mean level in 10 non-affected members from the kindreds studied was 1.5 ± 0.3 ng/ml. In the group of 12 nonanticoagulated heterozygous protein C-deficient individuals, the three patients with a history of venous thrombosis had a mean APC level significantly lower than the nine asymptomatic members (p <0.01), both subgroups showing similar protein C levels. There was a significant correlation in all groups between the levels of APC and the levels of protein C antigen (r = 0.758, p <0.0001) and activity (r = 0.745, p <0.0001), which means that APC circulating levels are proportional to protein C levels and suggests that the protein C level is the limiting factor in the rate of protein C activation in vivo.
Collapse
Affiliation(s)
- Francisco España
- The Research Center, “La Fe” University Hospital, Valencia, Spain
| | - Isabel Zuazu
- The Department of Medicine, School of Medicine, Murcia, Spain
| | - Vicente Vicente
- The Department of Medicine, School of Medicine, Murcia, Spain
| | - Amparo Estellés
- The Research Center, “La Fe” University Hospital, Valencia, Spain
| | - Pascual Marco
- The Hematology Service, General Hospital, Alicante, Spain
| | - Justo Aznar
- The Department of Clinical Pathology, “La Fe” University Hospital, Valencia, Spain
| |
Collapse
|
10
|
España F, Estellés A, Fernández PJ, Gilabert J, Sánchez-Cuenca J, Griffin JH. Evidence for the Regulation of Urokinase and Tissue Type Plasminogen Activators by the Serpin, Protein C Inhibitor, in Semen and Blood Plasma. Thromb Haemost 2018. [DOI: 10.1055/s-0038-1649712] [Citation(s) in RCA: 21] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
Abstract
SummarySince the serine protease inhibitor, protein C inhibitor (PCI), is present in seminal plasma at ≈3 μM, complexes of PCI with urokinase (uPA) and tissue type (tPA) plasminogen activator were quantitated using sandwich enzyme-linked immunosorbent assays (ELISA’s). Seminal plasma (N = 10) collected in the absence of extrinsic inhibitors had a mean of 25 ± 5 ng/ml uPA: PCI, 76 ± 23 ng/ml tPA: PCI, and 4 ± 2 ng/ml of tPA complexes with plasminogen activator inhibitor-1 (tPA:PAI-l). 93% of the uPA and 17% of the tPA antigen in seminal plasma was in complex with PCI and, when complexation was inhibited by collecting semen into an 1,10-phenanthrolinium solution, 33% of the uPA and 7% of the tPA was complexed to PCI. Urine (N = 10) contained 4 ± 1 ng/ml uPA:PCI. In purified system, complexation of uPA and tPA to PCI paralleled the inhibition of the enzymes. In vitro studies in blood and seminal plasma showed that heparin stimulated complexation of uPA and tPA with PCI, suggesting that negatively charged glycosaminoglycans in blood vessels and in the reproductive system may regulate PCI reactions with uPA and tPA. These results suggest that PCI is a physiologic regulator of uPA and tPA in male reproductive tissues and raises questions about a potential role of PCI in human fertility and in uPA-dependent cell invasiveness.
Collapse
Affiliation(s)
| | - Amparo Estellés
- Research Center, “La Fe” University Hospital, Valencia, Spain
| | - Pedro J Fernández
- The Department of Obstetrics and Gynecology, “La Fe” University Hospital, Valencia, Spain
| | - Juan Gilabert
- The Department of Obstetrics and Gynecology, “La Fe” University Hospital, Valencia, Spain
| | | | - John H Griffin
- The Committee on Vascular Biology and the Department of Molecular and Experimental Medicine, The Scripps Research Institute, La Jolla, CA, USA
| |
Collapse
|
11
|
Gilabert J, Estellés A, Aznar J, España F, Andrés C, Santos T, Vallés J. Contribution of Platelets to Increased Plasminogen Activator Inhibitor Type 1 in Severe Preeclampsia. Thromb Haemost 2018. [DOI: 10.1055/s-0038-1645047] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
Abstract
SummaryPlasminogen activator inhibitor activity and antigen were evaluated in plasma, serum and platelet lysate in patients with severe preeclampsia (n = 12), and in normal pregnant women (n = 21). Other parameters, including β-thromboglobulin and platelet count, were also evaluated. A significant increase (p <0.05) in β-thromboglobulin was observed in platelet poor plasma of preeclamptic women when compared with that of normal pregnant women, and the platelet count was lower in the preeclamptic group than in the normal pregnant group. A significant increase in plasminogen activator inhibitor activity and antigen was observed in platelet poor plasma of the preeclamptic group as compared with normal pregnant women, whereas platelet lysate from preeclamptic women showed a significant decrease in both plasminogen activator inhibitor activity and antigen as compared with that of normal pregnant women. No correlation between β-thromboglobulin and plasminogen activator inhibitor type 1 antigen in platelet poor plasma was observed, but a significant inverse correlation (r = −0.78, p <0.05) between β-thromboglobulin in platelet poor plasma and plasminogen activator inhibitor-1 antigen in platelet lysate was obtained in preeclamptic patients. However, in platelet poor plasmas obtained from normal platelet rich plasmas activated with thrombin (0.1 IU/ml, 37° C, 1 min), an increase of about 300 ng/ ml in β-thromboglobulin was observed while the increase in plasminogen activator inhibitor was only 4 ng/ml. It is concluded that the contribution of platelet plasminogen activator inhibitor-1 to the increase in plasma plasminogen activator inhibitor-1 levels in preeclamptic patients is negligible but the possibility that intravascular platelet activation indirectly contributes “in vivo” to the increase in plasma plasminogen activator inhibitor-1 levels in severe preeclampsia patients cannot be ruled out.
Collapse
Affiliation(s)
- Juan Gilabert
- The Department of Obstetrics and Gynecology, Hospital “La Fe”, Valencia, Spain
| | | | - Justo Aznar
- The Department of Clinical Pathology, Hospital “La Fe”, Valencia, Spain
| | | | | | - Teresa Santos
- The Research Center, Hospital “La Fe”, Valencia, Spain
| | - Juana Vallés
- The Research Center, Hospital “La Fe”, Valencia, Spain
| |
Collapse
|
12
|
Tabernero D, España F, Vicente V, Estellés A, Gilabert J, Aznar J. Protein C Inhibitor and Other Components of the Protein C Pathway in Patients with Acute Deep Vein Thrombosis during Heparin Treatment. Thromb Haemost 2018. [DOI: 10.1055/s-0038-1645051] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
Abstract
SummaryThe protein C inhibitor (PCI) concentration and other parameters of the protein C pathway were studied in 19 patients with symptomatic acute deep vein thrombosis before and during the first 5 days of heparin treatment. The mean levels of PCI antigen and activity decreased rapidly and significantly during the first day of heparin therapy from 83 and 81% to 60 and 59% of the pooled normal human plasma (p <0.01), respectively, and to 56 and 54% after 5 days of treatment (p <0.01). In contrast, antithrom-bin III decreased progressively 25% during 5 days of heparin treatment. Protein C antigen and activity and total protein S remained unchanged during heparin treatment. Free protein S was decreased before heparin treatment (83%, p <0.05) and increased to normal values after 5 days of treatment. C4b-binding protein was significantly increased before and during heparin treatment (p <0.01). Activated protein C (APC) complexed to its two major plasma inhibitors, PCI and α1-antitrypsin (α1AT) were measured by specific ELISA’s. Before treatment, 18 of the 19 patients studied had increased levels of APC: α1AT complexes with a mean value of 27 ± 22 ng/ml (range, 6−86 ng/ml) compared to normal values (8 ± 2 ng/ml) and 12 of the patients also had detectable APC:PCI complex levels with a mean value of 11 ±17 ng/ml (range, 5−68 ng/ml). Both APC:inhibitor complexes decreased significantly during heparin treatment.
Collapse
Affiliation(s)
- D Tabernero
- The Department of Hematology, Hospital General, Salamanca, Spain
| | - F España
- The Research Center, Hospital La Fe, Valencia, Spain
| | - V Vicente
- The Department of Hematology, Hospital General, Salamanca, Spain
| | - A Estellés
- The Research Center, Hospital La Fe, Valencia, Spain
| | - J Gilabert
- The Departments of Obstetrics and Gynecology, Hospital La Fe, Valencia, Spain
| | - J Aznar
- The Clinical Pathology, Hospital La Fe, Valencia, Spain
| |
Collapse
|
13
|
Marí-Alexandre J, Barceló-Molina M, Belmonte-López E, García-Oms J, Estellés A, Braza-Boïls A, Gilabert-Estellés J. Micro-RNA profile and proteins in peritoneal fluid from women with endometriosis: their relationship with sterility. Fertil Steril 2018; 109:675-684.e2. [PMID: 29605406 DOI: 10.1016/j.fertnstert.2017.11.036] [Citation(s) in RCA: 33] [Impact Index Per Article: 5.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/27/2017] [Revised: 11/28/2017] [Accepted: 11/28/2017] [Indexed: 02/07/2023]
Abstract
OBJECTIVE To define the microRNA (miRNA) profile and its relationship with cytokines content in peritoneal fluid (PF) from endometriosis patients. DESIGN Case-control study. SETTING University hospital, research institute. PATIENT(S) One hundred twenty-six women with endometriosis (EPF) and 45 control women (CPF). MAIN OUTCOMES MEASURE(S) MiRNA arrays were prepared from six EPF and six CPF. Quantitative reverse transcription-polymerase chain reaction validation of nine selected miRNAs (miR-29c-3p, -106b-3p, -130a-3p, -150-5p, -185-5p, -195-5p, -451a, -486-5p, and -1343-5p) was performed. Vascular endothelial growth factor-A (VEGF-A), thrombospondin-1 (TSP-1), urokinase plasminogen activator (uPA), plasminogen activator inhibitor-1 (PAI-1), matrix metalloproteinase-3 (MMP3), tissue inhibitor of metalloproteinases type 1 (TIMP-1), interleukin (IL)-6, IL-8, IL-17A, macrophage inflammatory protein 1β (MIP1beta), platelet-derived growth factor α-polypeptide A, and regulated on activation, normal T cell expressed and secreted (RANTES) were quantified by ELISA and MILLIPLEX. RESULT(S) MiRNA arrays showed 126 miRNAs differentially expressed (fold change ±1.2) (78 down-regulated, 48 up-regulated) in EPF. Validation showed higher levels of miR-106b-3p, -451a, -486-5p, IL-6, IL-8, uPA, and TIMP-1 in EPF. In menstrual phase, EPF presented up-regulation of miR-106b-3p, -130a-3p, -150-5p, -185-5p, -451a, -486-5p, VEGF-A, IL-8, MIF 1β, uPA, and PAI-1 compared with other phases; however, CPF did not. MiRNA-486-5p was up-regulated in sterile EPF compared with sterile controls, and VEGF-A, IL-8, and TIMP-1 were increased in sterile and fertile EPF compared with fertile CPF. CONCLUSION(S) MiRNAs seem to be involved in the peritoneal alterations in endometriosis, suggesting new mechanisms by which ectopic lesions could implant in endometriosis patients; and to serve as biomarkers for fertility outcome prediction.
Collapse
Affiliation(s)
- Josep Marí-Alexandre
- Cardiopatías Familiares, Muerte Súbita y Mecanismos de Enfermedad (CaFaMuSMe) Unit, Health Research Institute La Fe, University Hospital La Fe, Valencia, Spain
| | - Moisés Barceló-Molina
- Cardiopatías Familiares, Muerte Súbita y Mecanismos de Enfermedad (CaFaMuSMe) Unit, Health Research Institute La Fe, University Hospital La Fe, Valencia, Spain
| | - Elisa Belmonte-López
- Cardiopatías Familiares, Muerte Súbita y Mecanismos de Enfermedad (CaFaMuSMe) Unit, Health Research Institute La Fe, University Hospital La Fe, Valencia, Spain
| | - Javier García-Oms
- Endoscopy and Gynecologic Oncology Unit, Hospital General Universitario, Valencia, Spain
| | - Amparo Estellés
- Cardiopatías Familiares, Muerte Súbita y Mecanismos de Enfermedad (CaFaMuSMe) Unit, Health Research Institute La Fe, University Hospital La Fe, Valencia, Spain
| | - Aitana Braza-Boïls
- Cardiopatías Familiares, Muerte Súbita y Mecanismos de Enfermedad (CaFaMuSMe) Unit, Health Research Institute La Fe, University Hospital La Fe, Valencia, Spain.
| | - Juan Gilabert-Estellés
- Endoscopy and Gynecologic Oncology Unit, Hospital General Universitario, Valencia, Spain; Department of Pediatrics, Obstetrics, and Gynecology, University of Valencia, Valencia, Spain
| |
Collapse
|
14
|
Vayá A, Mira Y, Medina P, Estellés A, Villa P, Falcó C, Aznar J, España F. Low Level of Circulating Activated Protein C Is a Risk Factor for Venous Thromboembolism. Thromb Haemost 2017. [DOI: 10.1055/s-0037-1616737] [Citation(s) in RCA: 26] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
Abstract
SummaryThe levels of circulating activated protein C (APC) reflect in vivo protein C activation. The aim of this study was to determine whether a low APC level is an independent risk factor for venous thromboembolism (VTE). We measured APC in 160 patients with a history of VTE and without recognized thrombophilic defects, and in 199 healthy individuals. The mean (±SD) APC level was lower in patients (0.99 ± 0.44 ng/ml) than in controls (1.19 ± 0.41 ng/ml) (p <0.0001), and showed a different distribution in the two groups. Thirty-eight patients (23.7%) had APC levels below the 5th percentile of the control group (<0.69 ng/ml) and 57 patients (35.6%) had APC levels below the 10th percentile (<0.77 ng/ml). APC levels <0.69 ng/ml increased the risk of a single or recurrent episode of VTE 4.2-fold (95% confidence interval, 2.0-9.0) or 6.9-fold (2.6-17.9), respectively, and APC levels <0.77 ng/ml increased these risks 3.4-fold (1.9-6.2) or 5.1-fold (2.3-11.2), respectively, compared with controls. Familial studies revealed that in some cases the low APC phenotype seems to be hereditary. We conclude that a low level of circulating APC in individuals without any of the most recognized thrombophilic defects is a prevalent, independent risk factor for VTE, and that it predisposes to recurrent VTE.
Collapse
|
15
|
Dalmau J, Falcó C, Berbel O, Castelló R, España F, Aznar J, Estellés A. Plasma PAI-1 Levels in Obese Children – Effect of Weight Loss and Influence of PAI-1 Promoter 4G/5G Genotype. Thromb Haemost 2017. [DOI: 10.1055/s-0037-1616100] [Citation(s) in RCA: 24] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
Abstract
SummaryAn association between an increase in plasminogen activator inhibitor type 1 (PAI-1) and obesity, and also between elevated levels of PAI-1 and the presence of PAI-1 promoter 4G allele has been described in adults and can contribute to increased risk of cardiovascular disease. It has also been suggested that in adults a decrease in adiposity has beneficial effects on the haemostatic system. However, less information is available regarding adiposity and fibrinolysis in children. The aim of the present study is to evaluate the effect of weight loss and the influence of the PAI-1 promoter 4G/5G genotype on the fibrinolytic system and lipid parameters in obese children. The clinical groups included 102 obese children and 105 controls of similar age and sex distribution. A significant decrease in fibrinolytic activity due to a significant increase in PAI-1 antigen and activity levels was observed in the obese children in comparison with the control group. In obese children, no significant differences in PAI-1 levels between the PAI-1 4G/5G genotypes were obtained. A significant correlation was observed between PAI-1 antigenic and functional levels and body mass index (BMI), as well as between PAI-1 levels and both triglyceride and insulin levels. No correlation between PAI-1 levels and either cholesterol or glucose levels was observed.After a three-month period of treatment to reduce weight, an increase in fibrinolytic activity due to a decrease in PAI-1 levels was observed in the obese children who had reduced their BMI in comparison with the group of obese children who did not show a decrease in their BMI. No significant differences between the two groups with respect to the variations in tissue type plasminogen activator and fibrinogen levels were obtained after three months of intervention to reduce weight. A significant correlation was observed between variations in BMI and variations in PAI-1 levels, and a significant inverse correlation was also observed between previous PAI-1 levels and variation in PAI-1 levels. Therefore, the largest decrease in PAI-1 levels was observed in the obese children with the highest previous PAI-1 levels.In conclusion, a decrease in BMI in obese children shows a favourable effect on the fibrinolytic system due to a decrease in PAI-1 levels. However, no influence of 4G/5G genotype on PAI-1 levels was observed.
Collapse
|
16
|
Grancha S, Estellés A, Tormo G, Falco C, Gilabert J, España F, Cano A, Segui R, Aznar J. Plasminogen Activator Inhibitor-1 (PAI-1) Promoter 4G/5G Genotype and Increased PAI-1 Circulating Levels in Postmenopausal Women with Coronary Artery Disease. Thromb Haemost 2017. [DOI: 10.1055/s-0037-1614516] [Citation(s) in RCA: 37] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
Abstract
SummaryIncreased circulating levels of type 1 plasminogen activator inhibitor (PAI-1) have been associated with coronary artery disease (CAD). However, genetic and environmental determinants of PAI-1 expression are only partially understood. The levels of PAI-1 have been found to relate to 4/5 guanosine (4G/5G) polymorphism in the promoter region of the PAI-1 gene. The 4G allele in this polymorphism has been associated with higher levels of plasma PAI-1 activity, but despite the strong correlation between PAI-1 activity and antigen, no association has been found between PAI-1 antigen levels and the PAI-1 promoter 4G/5G genotype. The aim of the present study was to analyze the influence of the PAI-1 promoter 4G/5G genotype on PAI-1 levels in post-menopause women with coronary disease in comparison with healthy women in pre and postmenopausal status, and the influence of this genotype on variations in PAI-1 levels after hormone replacement therapy (HRT). No differences between 4G/5G allele distribution in the groups studied were observed. The group of postmenopausal women with CAD showed significantly increased PAI-1 antigen and activity levels in comparison with the control groups, and the levels of PAI-1 correlated with the 4G/5G genotype. A multivariate analysis revealed that in the CAD group there was a high correlation between 4G allele dosage and PAI-1 antigen levels, which were also influenced by the triglyceride levels but not by estrogen or glucose levels. After hormone replacement therapy the decrease in PAI-1 levels was correlated with the 4G allele dosage. We conclude that in the group of postmenopausal women with CAD the influence of the PAI-1 promoter 4G/5G genotype on PAI-1 levels is more evident than in the control groups, and that the decrease in PAI-1 levels after HRT in CAD women correlates with the 4G allele dosage.
Collapse
|
17
|
Villa P, Vaya A, España F, Ferrando F, Mira Y, Estellés A, Aznar J. Hereditary Homozygous Heparin Cofactor II Deficiency and the Risk of Developing Venous Thrombosis. Thromb Haemost 2017. [DOI: 10.1055/s-0037-1614320] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
Abstract
SummaryHeparin cofactor II (HCII) is a specific inhibitor of thrombin in the presence of heparin or dermatan sulphate. Although there have been reports on families in which a heterozygous HCII deficiency is associated with thromboembolic events, several epidemiological studies revealed that heterozygous HCII deficiency is as prevalent among healthy subjects as it is among patients with deep venous thrombosis (DVT). It is therefore not yet clear whether HCII is or is not a thrombotic risk factor.We analyze and describe in an extended family the biochemical and genetic thrombophilic risk factors and evaluate the potential thrombotic risk involved in homozygous and heterozygous HCII deficiency, either alone or associated with other thrombotic or circumstantial risk factors. The propositus has had three episodes of DVT and a pulmonary embolism. During the first episode of DVT the patient was diagnosed as having AT deficiency. Later, a functional and antigenic HCII deficiency, compatible with the homozygous form, was detected. The family study shows that both the propositus and her sister have homozygous HCII deficiency and that 12 of the 27 family members have heterozygous HCII deficiency.This is possibly the first case report on a homozygous phenotype for the HCII deficiency with, in addition, partial AT deficiency. The propositus has suffered several thrombotic events, unlike the other 12 family members with heterozygous HCII deficiency and her sister, who is also homozygous for this disorder. We suggest that HCII deficiency may play a limited in vivo role as a thrombotic risk factor unless associated with AT deficiency or another congenital thrombotic risk factor.
Collapse
|
18
|
Cano A, Falcó C, España F, Gilabert J, Grancha S, Aznar J, Estellés A. Lipoprotein(a) Levels and Isoforms and Fibrinolytic Activity in Postmenopause – Influence of Hormone Replacement Therapy. Thromb Haemost 2017. [DOI: 10.1055/s-0037-1614426] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
Abstract
SummaryEpidemiological studies suggest that hormone replacement therapy (HRT) decreases the risk of cardiovascular disease in postmenopausal women via several mechanisms, including modifications in the fibrinolytic system and lipoprotein(a) [Lp(a)] levels. The aim of this study was to examine the influence of the levels and isoforms of Lp(a) on fibrinolytic activity in 91 postmenopausal women in comparison with premenopause and analyze the effect of HRT on those parameters. In postmenopause, an increase in plasma Lp(a) and plasminogen activator inhibitor-1 (PAI-1) levels was found. A significant inverse correlation was observed between Lp(a) or PAI-1 levels and plasmin generation. Plasma samples with low molecular weight (MW) apo(a) isoforms showed higher plasmin inhibition than plasmas with high MW apo(a) isoforms and similar levels of total Lp(a) and PAI-1. HRT induced a significant decrease in Lp(a) and PAI-1 levels and an increase in estradiol levels, as well as an increase in fibrinolytic activity. A significant correlation was found between the percentages of variation in Lp(a) levels and in plasmin generation and between the percentages of variation in PAI-1 levels and in the euglobulin lysis time under HRT. In conclusion, the increase in fibrinolytic activity observed in women under HRT could be explained by two independent mechanisms: (a) the decrease in PAI-1 and (b) the decrease in the inhibition of plasmin generation due to the decrease in Lp(a) levels.
Collapse
|
19
|
Falcó C, Dalmau J, España F, Aznar J, Estellés A. Influence of Lipoprotein (a) Levels and Isoforms on Fibrinolytic Activity – Study in Families with High Lipoprotein (a) Levels. Thromb Haemost 2017. [DOI: 10.1055/s-0037-1615071] [Citation(s) in RCA: 15] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
Abstract
SummaryIncreased levels of lipoprotein (a) [Lp(a)] have been considered an independent risk factor for cardiovascular disease, but the mechanism behind this relationship is not completely understood. A high concentration of Lp(a) may interfere with fibrinolysis because of the structural similarity between apo(a) and plasminogen. The aim of the present study was to examine the influence of apo(a) levels and isoforms on fibrinolytic activity in 82 subjects from 24 families in which the Lp(a) levels were ≥30 mg/dl in at least one child and one parent. Several fibrinolytic parameters, including plasmin generation by fibrin-bound tissue plasminogen activator, the lipid profile and apo(a) isoforms were studied. Subjects with high circulating Lp(a) levels (n = 44) had significantly reduced plasmin generation compared with their relatives with normal Lp(a) levels (n = 38). A significant inverse correlation between Lp(a) levels and plasmin generation was observed. The individuals with a combination of high levels of plasma Lp(a) and a major apo(a) isoform ≤580 kD molecular weight show the lowest fibrinolytic activity. A high correlation was found between the levels of apo(a) isoforms in children and the levels of the corresponding parental apo(a) iso-forms. We conclude that the antifibrinolytic effect of Lp(a) in subjects with two apo(a) isoforms may depend not only on the total plasma level of Lp(a) but also on the relative concentration of the small apo(a) isoform.
Collapse
|
20
|
Gilabert J, Grancha S, Yamamoto K, Thinnes T, España F, Aznar J, Loskutoff D, Estellés A. Abnormal Expression of Type 1 Plasminogen Activator Inhibitor and Tissue Factor in Severe Preeclampsia. Thromb Haemost 2017. [DOI: 10.1055/s-0037-1614933] [Citation(s) in RCA: 53] [Impact Index Per Article: 7.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
Abstract
SummaryPreeclampsia is a multisystemic obstetric disease of unknown etiology that is commonly associated with fibrin deposition, occlusive lesions in placental vasculature, and intrauterine fetal growth retardation. We previously reported that type 1 plasminogen activator inhibitor (PAI-1) levels are significantly increased in plasma and placenta from pregnant women with preeclampsia compared to normal pregnant women. In the present report we localize the expression of placental PAI-1 in greater detail and compare it with that of tissue factor (TF), a procoagulant molecule, and vitronectin (Vn), a PAI-1 cofactor. We also examine the expression of two cytokines, tumor necrosis factor α (TNFα) and interleukin-1 (IL-1), in order to begin to define the underlying mechanisms responsible for the elevated levels of PAI-1 and fibrin deposits observed in placenta from preeclampsia. We demonstrate a significant increase in PAI-1, TF and TNFα antigen and PAI-1 and TF mRNA in placentas from preeclamptic patients. PAI-1 mRNA was increased not only in syncytiotrophoblast and infarction areas, but also in fibroblasts and in some endothelial cells of fetal vessels in placentas from preeclamptic patients. However, there was no colocalization between PAI-1, TF, Vn and TNFα in placental villi. The elevated TNFα in the placenta may induce PAI-1 and TF, and thus promote the thrombotic alterations associated with preeclampsia.
Collapse
|
21
|
Aznar J, Mira Y, Vayá A, Corella D, Ferrando F, Villa P, Estellés A. Factor V Leiden and prothrombin G20210A mutations in young adults with cryptogenic ischemic stroke. Thromb Haemost 2017; 91:1031-4. [PMID: 15116266 DOI: 10.1160/th03-11-0690] [Citation(s) in RCA: 50] [Impact Index Per Article: 7.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Abstract
SummaryThe association between factor V Leiden (FVL) and prothrombin G20210A (PT 20210) mutations and ischemic stroke remains controversial, particularly in young adults with cryptogenic stroke. Prevalence of FVL (4.1%) and PT 20210 (8.2%) mutations was assessed in 49 patients under 50 years with cryptogenic stroke and compared with controls. Odd ratio (OR) for cryptogenic stroke was 2.62 (95% CI, 0.49-13.95) for FVL and 3.75 (95% CI, 1.05-13.34) for PT 20210 and 3.28 (95% CI, 1,17-9.20) for some recognized genetic thrombophilic defect. Moreover, the OR for cryptogenic stroke in young women using oral contraceptives (OC) was 3.59 (95% CI, 1.28-10.5). When some genetic thrombophilic defect was associated with OC, the OR was much higher (OR: 14.27; 95% CI, 0.66-309.99). Our results suggest that in the Mediterranean populations the PT 20210 mutation, but not FV Leiden, is a risk factor for cryptogenic stroke in young adults. OC use is also a significant risk factor for cryptogenic stroke, which is increased in women with some genetic thrombotic risk factor.
Collapse
Affiliation(s)
- Justo Aznar
- La Fe University Hospital, Department of Clinical Pathology, Avd. Campanar 21, 46009 Valencia, Spain.
| | | | | | | | | | | | | |
Collapse
|
22
|
Ricart J, Todolí J, Calvo J, Villa P, Estellés A, España F, Santaolaria M, Corella D, Aznar J, Vayá A. Thrombophilic risk factors and homocysteine levels in Behçet’s disease in eastern Spain and their association with thrombotic events. Thromb Haemost 2017. [DOI: 10.1160/th05-10-0659] [Citation(s) in RCA: 39] [Impact Index Per Article: 5.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Abstract
SummaryBehçet’s disease (BD) is a chronic inflammatory disorder in which thrombosis occurs in about 30% of patients. The prothrombotic mechanisms are unknown. Thrombophilic defects and hyperhomocysteinaemia may be involved in the pathogenesis of thrombotic events, although results have been controversial. Moreover, no information is available on this issue for eastern Spain.We studied the prevalence of inherited and acquired thrombophilic risk factors in 79 patients with BD (43 men, 36 women) who had (n = 23) or did not have (n = 56) thrombosis, and in 84 healthy control subjects (42 men, 42 women). Risk factors examined were antithrombin, protein C and protein S levels, factor V Leiden, the prothrombin G20210A mutation, the methylenetetrahydrofolate reductase C677T polymorphism, and acquired thrombophilic risk factors, including anticardiolipin antibodies, lupus anticoagulant, and serum homocysteine levels. There were no differences between patients and controls in any of the parameters studied.When we studied BD patients with and without thrombotic events, the only thrombophilic defect that differed was the prothrombin G20210A mutation: Three out of 23 patients with thrombosis were carriers, compared with none of 56 patients without thrombosis (p = 0.022).Two of the three carriers developed catastrophic or recurrent thrombotic episodes; one wasa homozygous carrier of the G20210A prothrombin mutation and the other was doubly heterozygous for the G20210A prothrombin mutation and factor V Leiden. A meta-analysis demonstrated an association of factor V Leiden and prothrombin mutation with thrombosis in BD. When studies from Turkey were excluded from the meta-analysis, only the prothrombin G20210A mutation was associated with thrombosis.
Collapse
|
23
|
Abstract
SummaryThe protein C anticoagulant pathway plays a crucial role as a regulator of the blood clotting cascade. Protein C is activated on the vascular endothelial cell membrane by the thrombin-thrombomodulin complex. Once formed, activated protein C (APC) down-regulates thrombin formation by inactivating factors (F)Va and FVIIIa. Endothelial protein C receptor (EPCR) is able to bind protein C and increase the rate of protein C activation. Normal APC generation depends on the precise assemblage, on the surface of endothelial cells, of thrombin, thrombomodulin, protein C and EPCR.Therefore, any change in the efficiency of this assemblage may cause reduced/increased APC generation and modify the risk of thrombosis. This review highlights the different mutations/polymorphisms reported in the EPCR gene and their association with the risk of thrombosis.
Collapse
|
24
|
Roldán V, Ordoñez A, Marín F, Zorio E, Soria JM, Miñano A, España F, González-Conejero R, Pineda J, Estellés A, Fontcuberta J, Vicente V, Corral J. Antithrombin Cambridge II (A384S) supports a role for antithrombin deficiency in arterial thrombosis. Thromb Haemost 2017. [DOI: 10.1160/th08-09-0583] [Citation(s) in RCA: 30] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Abstract
SummaryAlthough the control of thrombin in the microvasculature at the endothelial cell surface is crucial to prevent atherothrombosis, the role of antithrombin in arterial thrombosis is unclear. It is widely considered that antithrombin deficiency is unlikely to contribute to arterial thrombosis, but no convincing epidemiological study has been performed because of the low frequency of this deficiency. In this study we evaluated the role in myocardial infarction (MI) of a relatively common mutation affecting antithrombin gene (A384S: Antithrombin Cambridge II) that has functional features that may impair the right control of thrombogenic events caused by injury to the vascular wall. Moreover, this deficiency, which is not detected using common methods to diagnose antithrombin deficiency, also increases the risk of venous thrombosis. We included 1,224 patients with MI (691 consecutive patients and 533 survivors of a premature event), and 1,649 controls. The mutation was identified in 0.3% of controls, but 0.8% of MI patients. After adjusting for sex and other cardiovascular risk factors, the antithrombin Cambridge II significantly increased 5.66-fold the risk of MI (95% CI: 1.53–20.88; p= 0.009). Interestingly, young patients had the highest risk of MI associated with the mutation (OR: 9.98; 95%CI: 1.60–62.24; p= 0.009). This is the first epidemiological study that supports a role for anti-thrombin deficiency in arterial thrombosis. These results suggest that deficiency of antithrombin may be an independent risk factor for MI that has been underestimated, but larger studies are needed to confirm the relevance of inhibitors of thrombin in arterial thrombosis.
Collapse
|
25
|
Medina P, Bonet E, Navarro S, Martos L, Estellés A, Ferrando F, Vicente V, Bertina RM, España F. Effects of oral anticoagulant therapy and haplotype 1 of the endothelial protein C receptor gene on activated protein C levels. Thromb Haemost 2017; 107:448-57. [DOI: 10.1160/th11-07-0510] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/22/2011] [Accepted: 12/05/2011] [Indexed: 11/05/2022]
Abstract
SummaryOral anticoagulants (OACs) reduce activated protein C (APC) plasma levels less than those of protein C (PC) in lupus erythematosus and cardiac patients. Carriers of the H1 haplotype of the endothelial PC receptor gene (PROCR) have higher APC levels than non-carriers. We aimed to confirm these results in a large group of patients treated with OACs because of venous thromboembolism (VTE) and to assess whether the effect is influenced by the PROCR H1 haplotype. We evaluated APC, PC, and factor (F)II levels in 502 VTE patients (158 with and 344 without OACs) and in 322 healthy individuals. Mean APC, PC and FII levels were significantly lower in OAC patients than in patients not taking OACs. During anticoagulant therapy, the FII/PC ratios were independent of the PC values, whereas APC/FII and APC/PC ratios significantly increased when FII and PC levels decreased. Of the 22 OAC patients carrying the H1H1genotype, 11 (50%) showed APC/PCag ≥2.0 and 10 (45%) APC/ FIIag ratios ≥2.0, whereas for the 49 OAC patients non-carrying the H1 haplotype these figures were 6 (12%) and 4 (8%), respectively (p<0.001). Barium citrate adsorption of plasma from OAC patients showed that most of the circulating free and complexed APC, but only part of PCag, is fully carboxylated. In conclusion, during anticoagulant therapy VT patients have APC levels disproportionately higher than the corresponding PC levels, mainly due to the presence of the PROCR H1 haplotype. Furthermore, a sufficiently carboxylated PC Gla-domain seems to be essential for PC activation in vivo.
Collapse
|
26
|
Braza-Boïls A, Salloum-Asfar S, Marí-Alexandre J, Arroyo AB, González-Conejero R, Barceló-Molina M, García-Oms J, Vicente V, Estellés A, Gilabert-Estellés J, Martínez C. Peritoneal fluid modifies the microRNA expression profile in endometrial and endometriotic cells from women with endometriosis. Hum Reprod 2015; 30:2292-302. [PMID: 26307093 DOI: 10.1093/humrep/dev204] [Citation(s) in RCA: 45] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/14/2015] [Accepted: 07/30/2015] [Indexed: 12/20/2022] Open
Abstract
STUDY QUESTION Could peritoneal fluid (PF) from patients with endometriosis alter the microRNA (miRNA) expression profile in endometrial and endometriotic cells from patients? SUMMARY ANSWER PF from patients with endometriosis modifies the miRNA expression profile in endometrial cells from patients. WHAT IS KNOWN ALREADY Angiogenesis is a pivotal system in the development of endometriosis, and dysregulated miRNA expression in this disease has been reported. However, to our knowledge, the effect of PF from patients on the miRNA expression profile of patient endometrial cells has not been reported. Moreover, an effect of three miRNAs (miR-16-5p, miR-29c-3p and miR-424-5p) on the regulation of vascular endothelial growth factor (VEGF)-A mRNA translation in endometrial cells from patients with endometriosis has not been demonstrated. STUDY DESIGN, SIZE, DURATION Primary cultures of stromal cells from endometrium from 8 control women (control cells) and 11 patients with endometriosis (eutopic cells) and ovarian endometriomas (ectopic cells) were treated with PF from control women (CPF) and patients (EPF) or not treated (0PF) in order to evaluate the effect of PF on miRNA expression in these cells. PARTICIPANTS/MATERIALS, SETTING, METHODS MiRNA expression arrays (Affymetrix platform) were prepared from cells (control, eutopic, ectopic) treated with CPF, EPF or 0PF. Results from arrays were validated by quantitative reverse transcription-polymerase chain reaction in cultures from 8 control endometrium, 11 eutopic endometrium and 11 ovarian endometriomas. Functional experiments were performed in primary cell cultures using mimics for miRNAs miR-16-5p, miR-29c-3p and miR-424-5p to assess their effect as VEGF-A expression regulators. To confirm a repressive action of miR-29c-3p through forming miRNA:VEGFA duplexes, we performed luciferase expression assays. MAIN RESULTS AND THE ROLE OF CHANCE EPF modified the miRNA expression profile in eutopic cells. A total of 267 miRNAs were modified in response to EPF compared with 0PF in eutopic cells. Nine miRNAs (miR-16-5p, miR-21-5p, miR-29c-3p, miR-106b-5p, miR-130a-5p, miR-149-5p, miR-185-5p, miR-195-5p, miR-424-5p) that were differently expressed in response to EPF, and which were potential targets involved in angiogenesis, proteolysis or endometriosis, were validated in further experiments (control = 8, eutopic = 11, ectopic = 11). Except for miR-149-5p, all validated miRNAs showed significantly lower levels (miR-16-5p, miR-106b-5p, miR-130a-5p; miR-195-5p and miR-424-5p, P < 0.05; miR-21-5p, miR-29c-3p and miR-185-5p, P < 0.01) after EPF treatment in primary cell cultures from eutopic endometrium from patients in comparison with 0PF. Transfection of stromal cells with mimics of miRNAs miR-16-5p, miR-29c-3p and miR-424-5p showed a significant down-regulation of VEGF-A protein expression. However, VEGFA mRNA expression after mimic transfection was not significantly modified, indicating the miRNAs inhibited VEGF-A mRNA translation rather than degrading VEGFA mRNA. Luciferase experiments also corroborated VEGF-A as a target gene of miR-29c-3p. LIMITATIONS, REASONS FOR CAUTION The study was performed in an in vitro model of endometriosis using stromal cells. This model is just a representation to try to elucidate the molecular mechanisms involved in the development of endometriosis. Further studies to identify the pathways involved in this miRNA expression modification in response to PF from patients are needed. WIDER IMPLICATIONS OF THE FINDINGS This is the first study describing a modified miRNA expression profile in eutopic cells from patients in response to PF from patients. These promising results improve the body of knowledge on endometriosis pathogenesis and could open up new therapeutic strategies for the treatment of endometriosis through the use of miRNAs. STUDY FUNDING/COMPETING INTERESTS This work was supported by research grants by ISCIII and FEDER (PI11/00091, PI11/00566, PI14/01309, PI14/00253 and FI12/00012), RIC (RD12/0042/0029 and RD12/0042/0050), IIS La Fe 2011-211, Prometeo 2011/027 and Contrato Sara Borrell CD13/0005. There are no conflicts of interest to declare.
Collapse
Affiliation(s)
- Aitana Braza-Boïls
- Grupo de Hemostasia, Trombosis, Aterosclerosis y Biología Vascular, Instituto de Investigación Sanitaria La Fe, Valencia, Spain
| | - Salam Salloum-Asfar
- Centro Regional de Hemodonación, Servicio de Hematología y Oncología Médica, Hospital Universitario Morales Meseguer, Universidad de Murcia, IMIB-Arrixaca, Murcia, Spain
| | - Josep Marí-Alexandre
- Grupo de Hemostasia, Trombosis, Aterosclerosis y Biología Vascular, Instituto de Investigación Sanitaria La Fe, Valencia, Spain
| | - Ana Belén Arroyo
- Centro Regional de Hemodonación, Servicio de Hematología y Oncología Médica, Hospital Universitario Morales Meseguer, Universidad de Murcia, IMIB-Arrixaca, Murcia, Spain
| | - Rocío González-Conejero
- Centro Regional de Hemodonación, Servicio de Hematología y Oncología Médica, Hospital Universitario Morales Meseguer, Universidad de Murcia, IMIB-Arrixaca, Murcia, Spain
| | - Moisés Barceló-Molina
- Grupo de Hemostasia, Trombosis, Aterosclerosis y Biología Vascular, Instituto de Investigación Sanitaria La Fe, Valencia, Spain
| | - Javier García-Oms
- Área Maternoinfantil, Hospital General Universitario, Valencia, Spain
| | - Vicente Vicente
- Centro Regional de Hemodonación, Servicio de Hematología y Oncología Médica, Hospital Universitario Morales Meseguer, Universidad de Murcia, IMIB-Arrixaca, Murcia, Spain
| | - Amparo Estellés
- Grupo de Hemostasia, Trombosis, Aterosclerosis y Biología Vascular, Instituto de Investigación Sanitaria La Fe, Valencia, Spain
| | | | - Constantino Martínez
- Centro Regional de Hemodonación, Servicio de Hematología y Oncología Médica, Hospital Universitario Morales Meseguer, Universidad de Murcia, IMIB-Arrixaca, Murcia, Spain
| |
Collapse
|
27
|
Marí-Alexandre J, García-Oms J, Barceló-Molina M, Gilabert-Aguilar J, Estellés A, Braza-Boíls A, Gilabert-Estellés J. MicroRNAs and angiogenesis in endometriosis. Thromb Res 2015; 135 Suppl 1:S38-40. [PMID: 25903532 DOI: 10.1016/s0049-3848(15)50439-8] [Citation(s) in RCA: 31] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
Abstract
miRNAs function as important regulators of a wide range of cellular processes, such as angiogenesis and fibrinolysis, by postranscriptional modulation of gene expression. We present a review on the role of miRNAs and angiogenesis in endometriosis. Endometriosis, defined as the implantation of endometrial tissue outside the uterine cavity, is one of the most frequent benign gynecological diseases and it has important consequences on the quality of life and fertility of patients. Similarly to tumor metastasis, the ectopic endometrium acquires the capability to adhere, proliferate and infiltrate the extracellular matrix. Endometriosis is a multifactorial and polygenic disease in which angiogenesis and proteolysis may be involved, and emerging data provide evidence that a dysregulation of miRNA expression may be implicated in these processes. The detection of circulating miRNAs in plasma and other body fluids and their relative stability has raised the possibility that they might serve as non-invasive biomarkers for the diagnosis of the disease. On the other hand, the development of therapies that might block the expression or mimic the functions of miRNAs could represent new therapeutic strategies for the treatment of endometriosis.
Collapse
Affiliation(s)
- Josep Marí-Alexandre
- Instituto de Investigación Sanitaria La Fe, Hospital Universitario y Politécnico La Fe, Valencia, Spain
| | - Javier García-Oms
- Area Maternoinfantil, Hospital General Universitario, Valencia, Spain
| | - Moisés Barceló-Molina
- Instituto de Investigación Sanitaria La Fe, Hospital Universitario y Politécnico La Fe, Valencia, Spain
| | | | - Amparo Estellés
- Instituto de Investigación Sanitaria La Fe, Hospital Universitario y Politécnico La Fe, Valencia, Spain
| | - Aitana Braza-Boíls
- Instituto de Investigación Sanitaria La Fe, Hospital Universitario y Politécnico La Fe, Valencia, Spain
| | | |
Collapse
|
28
|
Martos L, Ferrando F, Moret A, Navarro Rosales S, Medina P, Bonet E, Mira Y, Vayá A, Cabrera N, Estellés A, Bonanad S, España F. C0123: Combined Deficiency of Protein C, Protein S and Antithrombin in Patients with Mesenteric or Portal Venous Thrombosis with or without Hepatic Cirrhosis. Thromb Res 2014. [DOI: 10.1016/s0049-3848(14)50197-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
29
|
Martos L, Bonet E, Medina P, Vayá A, Lecumberri R, Ferrando F, Mira Y, Marco P, González-López TJ, Hermida J, Ibáñez F, Montes R, Estellés A, Bonanad S, Navarro Rosales S, España F. C0122: Identification of 6 Mutations in the Protein C Gene (PROC) in a Panel of 83 Spanish Families with Protein C Deficiency. Thromb Res 2014. [DOI: 10.1016/s0049-3848(14)50254-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
30
|
Braza-Boils A, Salloum-Asfar S, Marí-Alexandre J, Belén Arroyo A, González-Conejero R, Vicente V, Estellés A, Gilabert-Estellés J, Martínez C. C0418: miRNAs 16, 424 and 29C Regulate VEGF-A Expression in Endometrial Stromal Cells from Women with Endometriosis. Thromb Res 2014. [DOI: 10.1016/s0049-3848(14)50066-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
31
|
Marí-Alexandre J, Braza-Boils A, Molina P, Domingo D, Abellán Y, Sancho J, Hevia P, Ángel Arnau M, Gómez J, Giner J, Salvador A, Estellés A, Zorio E. C0423: MicroRNAs in Sudden Cardiac Death from Coronary Artery Disease. Its Relationship with Dyslipidemia and Non-Alcoholic Fatty Liver Disease. Thromb Res 2014. [DOI: 10.1016/s0049-3848(14)50068-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
32
|
Braza-Boils A, Marí-Alexandre J, Molina P, Domingo D, Sanz J, Sancho J, Abellán Y, Castillo N, Ángel Arnau M, Giner J, Montero A, Estellés A, Zorio E. C0420: MicroRNA Expression Profile in Epicardial Fat in Sudden Cardiac Death from Coronary Artery Disease. Thromb Res 2014. [DOI: 10.1016/s0049-3848(14)50067-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
33
|
Braza-Boïls A, Marí-Alexandre J, Gilabert J, Sánchez-Izquierdo D, España F, Estellés A, Gilabert-Estellés J. MicroRNA expression profile in endometriosis: its relation to angiogenesis and fibrinolytic factors. Hum Reprod 2014; 29:978-88. [PMID: 24608518 DOI: 10.1093/humrep/deu019] [Citation(s) in RCA: 113] [Impact Index Per Article: 11.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023] Open
Abstract
STUDY QUESTION Could an aberrant microRNA (miRNA) expression profile be responsible for the changes in the angiogenic and fibrinolytic states observed in endometriotic lesions? SUMMARY ANSWER This study revealed characteristic miRNA expression profiles associated with endometriosis in endometrial tissue and endometriotic lesions from the same patient and their correlation with the most important angiogenic and fibrinolytic factors. WHAT IS ALREADY KNOWN?: An important role for dysregulated miRNA expression in the pathogenesis of endometriosis is well documented. However, to the best of our knowledge, there are no reports of the relationship between angiogenic and fibrinolytic factors and miRNAs when endometrial tissue and different types of endometriotic lesions from the same patient are compared. STUDY DESIGN, SIZE, DURATION Case-control study that involved 51 women with endometriosis and 32 women without the disease (controls). PARTICIPANTS/MATERIALS, SETTING, METHODS The miRNA expression profiles were determined using the GeneChip miRNA 2.0 Affymetrix array platform, and the results were analysed using Partek Genomic Suite software. To validate the obtained results, 12 miRNAs differentially expressed were quantified by using miRCURY LNA™ Universal RT microRNA PCR. Levels of vascular endothelial growth factor (VEGF-A), thrombospondin-1 (TSP-1), urokinase plasminogen activator (uPA) and plasminogen activator inhibitor-1 (PAI-1) proteins were quantified by ELISA. MAIN RESULTS AND THE ROLE OF CHANCE Patient endometrial tissue showed significantly lower levels of miR-202-3p, miR-424-5p, miR-449b-3p and miR-556-3p, and higher levels of VEGF-A and uPA than healthy (control) endometrium. However, tissue affected by ovarian endometrioma showed significantly lower expression of miR-449b-3p than endometrium from both controls and patients, and higher levels of PAI-1 and the angiogenic inhibitor TSP-1. A significant inverse correlation between miR-424-5p and VEGF-A protein levels was observed in patient endometrium, and an inverse correlation between miR-449b-3p and TSP-1 protein levels was observed in ovarian endometrioma. Peritoneal implants had significantly higher levels of VEGF-A than ovarian endometrioma samples. LIMITATIONS, REASONS FOR CAUTION Functional studies are needed to confirm the specific targets of the miRNAs differently expressed. WIDER IMPLICATIONS OF THE FINDINGS Differences in miRNA levels could modulate the expression of VEGF-A and TSP-1, which may play an important role in the pathogenesis of endometriosis. The higher angiogenic and proteolytic activities observed in eutopic endometrium from patients might facilitate the implantation of endometrial cells at ectopic sites. STUDY FUNDING/COMPETING INTEREST(S) This work was supported by research grants from ISCIII-FEDER (PI11/0091, Red RIC RD12/0042/0029), Consellería de Educación-Generalitat Valenciana (PROMETEO/2011/027), Beca de Investigación Fundación Dexeus para la Salud de la Mujer (2011/0469), and by Fundación Investigación Hospital La Fe (2011/211). A.B-B. has a Contrato Posdoctoral de Perfeccionamiento Sara Borrell-ISCIII (CD13/00005). J.M-A. has a predoctoral grant PFIS-ISCIII (FI12/00012). The authors have no conflicts of interest to declare.
Collapse
Affiliation(s)
- Aitana Braza-Boïls
- Grupo de Hemostasia, Trombosis, Arteriosclerosis y Biología Vascular, Instituto Investigación Sanitaria Hospital La Fe (IIS La Fe), Valencia, Spain
| | | | | | | | | | | | | |
Collapse
|
34
|
Medina P, Navarro S, Bonet E, Martos L, Estellés A, Bertina R, Vos H, España F. Functional Analysis of Two Haplotypes of the Human Endothelial Protein C Receptor Gene. Arterioscler Thromb Vasc Biol 2014; 34:684-90. [DOI: 10.1161/atvbaha.113.302518] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Objective—
To confirm the effect of the endothelial protein receptor gene (
PROCR
) haplotypes H1 and H3 on venous thromboembolism (VTE), to study their effect on endothelial protein C receptor (EPCR) expression in human umbilical vein endothelial cells, and to investigate the functionality of H1 tagging single-nucleotide polymorphisms in an in vitro model.
Approach and Results—
Protein C (PC), activated PC, and soluble EPCR (sEPCR) levels were measured in 702 patients with VTE and 518 healthy individuals. All subjects were genotyped for
PROCR
H1 and H3. Human umbilical vein endothelial cells isolated from 111 umbilical cords were used to study the relation between
PROCR
haplotypes,
PROCR
mRNA, cellular distribution of EPCR, and rate of PC activation. Finally, the functionality of the intragenic
PROCR
H1 single-nucleotide polymorphisms was analyzed using a luciferase-based method. We confirmed that individuals carrying H1 have reduced VTE risk, increased plasma activated PC levels, and reduced plasma sEPCR levels and that individuals with the H3H3 genotype have an increased VTE risk and increased plasma sEPCR levels. In cultured human umbilical vein endothelial cells, H1 is associated with increased membrane-bound EPCR, increased rate of PC activation, and reduced sEPCR in conditioned medium, but does not significantly influence
PROCR
mRNA levels. In contrast, H3 is associated with reduced membrane-bound EPCR and increased sEPCR in human umbilical vein endothelial cell–conditioned medium, higher levels of a truncated mRNA isoform, and a lower rate of PC activation. Finally, we identified the g.2132T>C single-nucleotide polymorphism in intron 1 as an intragenic H1-specific functional single-nucleotide polymorphism.
Conclusions—
These results support a protective role of
PROCR
H1 against VTE and an increased risk of VTE associated with the H3 haplotype.
Collapse
Affiliation(s)
- P. Medina
- From the Grupo de Investigación en Hemostasia, Trombosis, Arteriosclerosis y Biología Vascular, Centro de Investigación (P.M., S.N., E.B., L.M., A.E., F.E.) and Servicio de Análisis Clínicos (E.B.), Hospital Universitario y Politécnico La Fe, Valencia, Spain; and Department of Thrombosis and Haemostasis, Einthoven Laboratory, Leiden University Medical Centre, Leiden, The Netherlands (R.M.B., H.L.V.)
| | - S. Navarro
- From the Grupo de Investigación en Hemostasia, Trombosis, Arteriosclerosis y Biología Vascular, Centro de Investigación (P.M., S.N., E.B., L.M., A.E., F.E.) and Servicio de Análisis Clínicos (E.B.), Hospital Universitario y Politécnico La Fe, Valencia, Spain; and Department of Thrombosis and Haemostasis, Einthoven Laboratory, Leiden University Medical Centre, Leiden, The Netherlands (R.M.B., H.L.V.)
| | - E. Bonet
- From the Grupo de Investigación en Hemostasia, Trombosis, Arteriosclerosis y Biología Vascular, Centro de Investigación (P.M., S.N., E.B., L.M., A.E., F.E.) and Servicio de Análisis Clínicos (E.B.), Hospital Universitario y Politécnico La Fe, Valencia, Spain; and Department of Thrombosis and Haemostasis, Einthoven Laboratory, Leiden University Medical Centre, Leiden, The Netherlands (R.M.B., H.L.V.)
| | - L. Martos
- From the Grupo de Investigación en Hemostasia, Trombosis, Arteriosclerosis y Biología Vascular, Centro de Investigación (P.M., S.N., E.B., L.M., A.E., F.E.) and Servicio de Análisis Clínicos (E.B.), Hospital Universitario y Politécnico La Fe, Valencia, Spain; and Department of Thrombosis and Haemostasis, Einthoven Laboratory, Leiden University Medical Centre, Leiden, The Netherlands (R.M.B., H.L.V.)
| | - A. Estellés
- From the Grupo de Investigación en Hemostasia, Trombosis, Arteriosclerosis y Biología Vascular, Centro de Investigación (P.M., S.N., E.B., L.M., A.E., F.E.) and Servicio de Análisis Clínicos (E.B.), Hospital Universitario y Politécnico La Fe, Valencia, Spain; and Department of Thrombosis and Haemostasis, Einthoven Laboratory, Leiden University Medical Centre, Leiden, The Netherlands (R.M.B., H.L.V.)
| | - R.M. Bertina
- From the Grupo de Investigación en Hemostasia, Trombosis, Arteriosclerosis y Biología Vascular, Centro de Investigación (P.M., S.N., E.B., L.M., A.E., F.E.) and Servicio de Análisis Clínicos (E.B.), Hospital Universitario y Politécnico La Fe, Valencia, Spain; and Department of Thrombosis and Haemostasis, Einthoven Laboratory, Leiden University Medical Centre, Leiden, The Netherlands (R.M.B., H.L.V.)
| | - H.L. Vos
- From the Grupo de Investigación en Hemostasia, Trombosis, Arteriosclerosis y Biología Vascular, Centro de Investigación (P.M., S.N., E.B., L.M., A.E., F.E.) and Servicio de Análisis Clínicos (E.B.), Hospital Universitario y Politécnico La Fe, Valencia, Spain; and Department of Thrombosis and Haemostasis, Einthoven Laboratory, Leiden University Medical Centre, Leiden, The Netherlands (R.M.B., H.L.V.)
| | - F. España
- From the Grupo de Investigación en Hemostasia, Trombosis, Arteriosclerosis y Biología Vascular, Centro de Investigación (P.M., S.N., E.B., L.M., A.E., F.E.) and Servicio de Análisis Clínicos (E.B.), Hospital Universitario y Politécnico La Fe, Valencia, Spain; and Department of Thrombosis and Haemostasis, Einthoven Laboratory, Leiden University Medical Centre, Leiden, The Netherlands (R.M.B., H.L.V.)
| |
Collapse
|
35
|
Navarro S, Medina P, Bonet E, Corral J, Martínez-Sales V, Martos L, Rivera M, Roselló-Lletí E, Alberca I, Roldán V, Mira Y, Ferrando F, Estellés A, Vicente V, Bertina RM, España F. Association of the Thrombomodulin Gene c.1418C>T Polymorphism With Thrombomodulin Levels and With Venous Thrombosis Risk. Arterioscler Thromb Vasc Biol 2013; 33:1435-40. [DOI: 10.1161/atvbaha.113.301360] [Citation(s) in RCA: 25] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Objective—
To investigate the association of the
THBD
c.1418C>T polymorphism, which encodes for the replacement of Ala455 by Val in thrombomodulin (TM), with venous thromboembolism (VTE), plasma soluble TM, and activated protein C levels. In addition, human umbilical vein endothelial cells (HUVEC) isolated from 100 umbilical cords were used to analyze the relation between this polymorphism and
THBD
mRNA and TM protein expression.
Approach and Results—
The
THBD
c.1418C>T polymorphism was genotyped in 1173 patients with VTE and 1262 control subjects. Levels of soluble TM and activated protein C were measured in 414 patients with VTE (not on oral anticoagulants) and 451 controls. HUVECs were genotyped for the polymorphism and analyzed for
THBD
mRNA and TM protein expression and for the ability to enhance protein C activation by thrombin. The 1418T allele frequency was lower in patients than in controls (
P
<0.001), and its presence was associated with a reduced VTE risk, reduced soluble TM levels, and increased circulating activated protein C levels (
P
<0.001). In cultured HUVEC, the 1418T allele did not influence
THBD
expression but was associated with increased TM in cell lysates, increased rate of protein C activation, and reduced soluble TM levels in conditioned medium.
Conclusions—
The
THBD
1418T allele is associated with lower soluble TM, both in plasma and in HUVEC-conditioned medium, and with an increase in functional membrane–bound TM in HUVEC, which could explain the increased activated protein C levels and the reduced VTE risk observed in individuals carrying this allele.
Collapse
Affiliation(s)
- Silvia Navarro
- From the Unidad de Bioquímica, Centro de Investigación, Hospital Universitario La Fe, Valencia, Spain (S.N., P.M., E.B., V.M.-S., L.M., A.E., F.E.); Servicio de Análisis Clínicos, Hospital Universitario La Fe, Valencia, Spain (E.B.); Centro Regional de Hemodonación, Universidad de Murcia, Spain (J.C., V.R., V.V.); Unidad de Cardiocirculación, Centro de Investigación, Hospital Universitario La Fe, Valencia, Spain (M.R., E.R.-L); Hematology Service, Hospital Clínico Universitario, Salamanca, Spain (I
| | - Pilar Medina
- From the Unidad de Bioquímica, Centro de Investigación, Hospital Universitario La Fe, Valencia, Spain (S.N., P.M., E.B., V.M.-S., L.M., A.E., F.E.); Servicio de Análisis Clínicos, Hospital Universitario La Fe, Valencia, Spain (E.B.); Centro Regional de Hemodonación, Universidad de Murcia, Spain (J.C., V.R., V.V.); Unidad de Cardiocirculación, Centro de Investigación, Hospital Universitario La Fe, Valencia, Spain (M.R., E.R.-L); Hematology Service, Hospital Clínico Universitario, Salamanca, Spain (I
| | - Elena Bonet
- From the Unidad de Bioquímica, Centro de Investigación, Hospital Universitario La Fe, Valencia, Spain (S.N., P.M., E.B., V.M.-S., L.M., A.E., F.E.); Servicio de Análisis Clínicos, Hospital Universitario La Fe, Valencia, Spain (E.B.); Centro Regional de Hemodonación, Universidad de Murcia, Spain (J.C., V.R., V.V.); Unidad de Cardiocirculación, Centro de Investigación, Hospital Universitario La Fe, Valencia, Spain (M.R., E.R.-L); Hematology Service, Hospital Clínico Universitario, Salamanca, Spain (I
| | - Javier Corral
- From the Unidad de Bioquímica, Centro de Investigación, Hospital Universitario La Fe, Valencia, Spain (S.N., P.M., E.B., V.M.-S., L.M., A.E., F.E.); Servicio de Análisis Clínicos, Hospital Universitario La Fe, Valencia, Spain (E.B.); Centro Regional de Hemodonación, Universidad de Murcia, Spain (J.C., V.R., V.V.); Unidad de Cardiocirculación, Centro de Investigación, Hospital Universitario La Fe, Valencia, Spain (M.R., E.R.-L); Hematology Service, Hospital Clínico Universitario, Salamanca, Spain (I
| | - Vicenta Martínez-Sales
- From the Unidad de Bioquímica, Centro de Investigación, Hospital Universitario La Fe, Valencia, Spain (S.N., P.M., E.B., V.M.-S., L.M., A.E., F.E.); Servicio de Análisis Clínicos, Hospital Universitario La Fe, Valencia, Spain (E.B.); Centro Regional de Hemodonación, Universidad de Murcia, Spain (J.C., V.R., V.V.); Unidad de Cardiocirculación, Centro de Investigación, Hospital Universitario La Fe, Valencia, Spain (M.R., E.R.-L); Hematology Service, Hospital Clínico Universitario, Salamanca, Spain (I
| | - Laura Martos
- From the Unidad de Bioquímica, Centro de Investigación, Hospital Universitario La Fe, Valencia, Spain (S.N., P.M., E.B., V.M.-S., L.M., A.E., F.E.); Servicio de Análisis Clínicos, Hospital Universitario La Fe, Valencia, Spain (E.B.); Centro Regional de Hemodonación, Universidad de Murcia, Spain (J.C., V.R., V.V.); Unidad de Cardiocirculación, Centro de Investigación, Hospital Universitario La Fe, Valencia, Spain (M.R., E.R.-L); Hematology Service, Hospital Clínico Universitario, Salamanca, Spain (I
| | - Miguel Rivera
- From the Unidad de Bioquímica, Centro de Investigación, Hospital Universitario La Fe, Valencia, Spain (S.N., P.M., E.B., V.M.-S., L.M., A.E., F.E.); Servicio de Análisis Clínicos, Hospital Universitario La Fe, Valencia, Spain (E.B.); Centro Regional de Hemodonación, Universidad de Murcia, Spain (J.C., V.R., V.V.); Unidad de Cardiocirculación, Centro de Investigación, Hospital Universitario La Fe, Valencia, Spain (M.R., E.R.-L); Hematology Service, Hospital Clínico Universitario, Salamanca, Spain (I
| | - Esther Roselló-Lletí
- From the Unidad de Bioquímica, Centro de Investigación, Hospital Universitario La Fe, Valencia, Spain (S.N., P.M., E.B., V.M.-S., L.M., A.E., F.E.); Servicio de Análisis Clínicos, Hospital Universitario La Fe, Valencia, Spain (E.B.); Centro Regional de Hemodonación, Universidad de Murcia, Spain (J.C., V.R., V.V.); Unidad de Cardiocirculación, Centro de Investigación, Hospital Universitario La Fe, Valencia, Spain (M.R., E.R.-L); Hematology Service, Hospital Clínico Universitario, Salamanca, Spain (I
| | - Ignacio Alberca
- From the Unidad de Bioquímica, Centro de Investigación, Hospital Universitario La Fe, Valencia, Spain (S.N., P.M., E.B., V.M.-S., L.M., A.E., F.E.); Servicio de Análisis Clínicos, Hospital Universitario La Fe, Valencia, Spain (E.B.); Centro Regional de Hemodonación, Universidad de Murcia, Spain (J.C., V.R., V.V.); Unidad de Cardiocirculación, Centro de Investigación, Hospital Universitario La Fe, Valencia, Spain (M.R., E.R.-L); Hematology Service, Hospital Clínico Universitario, Salamanca, Spain (I
| | - Vanessa Roldán
- From the Unidad de Bioquímica, Centro de Investigación, Hospital Universitario La Fe, Valencia, Spain (S.N., P.M., E.B., V.M.-S., L.M., A.E., F.E.); Servicio de Análisis Clínicos, Hospital Universitario La Fe, Valencia, Spain (E.B.); Centro Regional de Hemodonación, Universidad de Murcia, Spain (J.C., V.R., V.V.); Unidad de Cardiocirculación, Centro de Investigación, Hospital Universitario La Fe, Valencia, Spain (M.R., E.R.-L); Hematology Service, Hospital Clínico Universitario, Salamanca, Spain (I
| | - Yolanda Mira
- From the Unidad de Bioquímica, Centro de Investigación, Hospital Universitario La Fe, Valencia, Spain (S.N., P.M., E.B., V.M.-S., L.M., A.E., F.E.); Servicio de Análisis Clínicos, Hospital Universitario La Fe, Valencia, Spain (E.B.); Centro Regional de Hemodonación, Universidad de Murcia, Spain (J.C., V.R., V.V.); Unidad de Cardiocirculación, Centro de Investigación, Hospital Universitario La Fe, Valencia, Spain (M.R., E.R.-L); Hematology Service, Hospital Clínico Universitario, Salamanca, Spain (I
| | - Fernando Ferrando
- From the Unidad de Bioquímica, Centro de Investigación, Hospital Universitario La Fe, Valencia, Spain (S.N., P.M., E.B., V.M.-S., L.M., A.E., F.E.); Servicio de Análisis Clínicos, Hospital Universitario La Fe, Valencia, Spain (E.B.); Centro Regional de Hemodonación, Universidad de Murcia, Spain (J.C., V.R., V.V.); Unidad de Cardiocirculación, Centro de Investigación, Hospital Universitario La Fe, Valencia, Spain (M.R., E.R.-L); Hematology Service, Hospital Clínico Universitario, Salamanca, Spain (I
| | - Amparo Estellés
- From the Unidad de Bioquímica, Centro de Investigación, Hospital Universitario La Fe, Valencia, Spain (S.N., P.M., E.B., V.M.-S., L.M., A.E., F.E.); Servicio de Análisis Clínicos, Hospital Universitario La Fe, Valencia, Spain (E.B.); Centro Regional de Hemodonación, Universidad de Murcia, Spain (J.C., V.R., V.V.); Unidad de Cardiocirculación, Centro de Investigación, Hospital Universitario La Fe, Valencia, Spain (M.R., E.R.-L); Hematology Service, Hospital Clínico Universitario, Salamanca, Spain (I
| | - Vicente Vicente
- From the Unidad de Bioquímica, Centro de Investigación, Hospital Universitario La Fe, Valencia, Spain (S.N., P.M., E.B., V.M.-S., L.M., A.E., F.E.); Servicio de Análisis Clínicos, Hospital Universitario La Fe, Valencia, Spain (E.B.); Centro Regional de Hemodonación, Universidad de Murcia, Spain (J.C., V.R., V.V.); Unidad de Cardiocirculación, Centro de Investigación, Hospital Universitario La Fe, Valencia, Spain (M.R., E.R.-L); Hematology Service, Hospital Clínico Universitario, Salamanca, Spain (I
| | - Rogier M. Bertina
- From the Unidad de Bioquímica, Centro de Investigación, Hospital Universitario La Fe, Valencia, Spain (S.N., P.M., E.B., V.M.-S., L.M., A.E., F.E.); Servicio de Análisis Clínicos, Hospital Universitario La Fe, Valencia, Spain (E.B.); Centro Regional de Hemodonación, Universidad de Murcia, Spain (J.C., V.R., V.V.); Unidad de Cardiocirculación, Centro de Investigación, Hospital Universitario La Fe, Valencia, Spain (M.R., E.R.-L); Hematology Service, Hospital Clínico Universitario, Salamanca, Spain (I
| | - Francisco España
- From the Unidad de Bioquímica, Centro de Investigación, Hospital Universitario La Fe, Valencia, Spain (S.N., P.M., E.B., V.M.-S., L.M., A.E., F.E.); Servicio de Análisis Clínicos, Hospital Universitario La Fe, Valencia, Spain (E.B.); Centro Regional de Hemodonación, Universidad de Murcia, Spain (J.C., V.R., V.V.); Unidad de Cardiocirculación, Centro de Investigación, Hospital Universitario La Fe, Valencia, Spain (M.R., E.R.-L); Hematology Service, Hospital Clínico Universitario, Salamanca, Spain (I
| |
Collapse
|
36
|
Braza-Boïls A, Gilabert-Estellés J, Ramón LA, Gilabert J, Marí-Alexandre J, Chirivella M, España F, Estellés A. Peritoneal fluid reduces angiogenesis-related microRNA expression in cell cultures of endometrial and endometriotic tissues from women with endometriosis. PLoS One 2013; 8:e62370. [PMID: 23620826 PMCID: PMC3631199 DOI: 10.1371/journal.pone.0062370] [Citation(s) in RCA: 31] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/02/2012] [Accepted: 03/20/2013] [Indexed: 02/06/2023] Open
Abstract
Endometriosis, defined as the presence of endometrium outside the uterus, is one of the most frequent gynecological diseases. It has been suggested that modifications of both endometrial and peritoneal factors could be implicated in this disease. Endometriosis is a multifactorial disease in which angiogenesis and proteolysis are dysregulated. MicroRNAs (miRNAs) are small non-coding RNAs that regulate the protein expression and may be the main regulators of angiogenesis. Our hypothesis is that peritoneal fluid from women with endometriosis could modify the expression of several miRNAs that regulate angiogenesis and proteolysis in the endometriosis development. The objective of this study has been to evaluate the influence of endometriotic peritoneal fluid on the expression of six miRNAs related to angiogenesis, as well as several angiogenic and proteolytic factors in endometrial and endometriotic cell cultures from women with endometriosis compared with women without endometriosis.
Collapse
Affiliation(s)
- Aitana Braza-Boïls
- Grupo de Hemostasia, Trombosis, Arteriosclerosis y Biología Vascular, Instituto Investigación Sanitaria Hospital La Fe, Valencia, Spain
| | | | - Luis A. Ramón
- Grupo de Hemostasia, Trombosis, Arteriosclerosis y Biología Vascular, Instituto Investigación Sanitaria Hospital La Fe, Valencia, Spain
| | - Juan Gilabert
- Servicio de Ginecología, Hospital Arnau de Vilanova, Valencia, Spain
| | - Josep Marí-Alexandre
- Grupo de Hemostasia, Trombosis, Arteriosclerosis y Biología Vascular, Instituto Investigación Sanitaria Hospital La Fe, Valencia, Spain
| | - Melitina Chirivella
- Departamento de Anatomopatología, Hospital Universitario y Politécnico La Fe, Valencia, Spain
| | - Francisco España
- Centro de Investigación, Hospital Universitario y Politécnico La Fe, Valencia, Spain
| | - Amparo Estellés
- Centro de Investigación, Hospital Universitario y Politécnico La Fe, Valencia, Spain
- * E-mail:
| |
Collapse
|
37
|
Bonet E, Navarro S, Medina P, Martos L, Ferrando F, Vayá A, Mira Y, Aznar JA, Estellés A, Bertina RM, España F. C0069 Association of haplotypes (H) 1 and 3 of the endothelial protein c receptor gene (PROCR) with venous thromboembolism. Thromb Res 2012. [DOI: 10.1016/j.thromres.2012.08.027] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
38
|
Ramón LA, Braza-Boils A, Gilabert-Estellés J, Aguilar JG, Casanova MC, Furió FE, Estellés A. C0182 Dysregulated micrornas related to angiogenesis expression in endometrial cancer. Thromb Res 2012. [DOI: 10.1016/j.thromres.2012.08.243] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
39
|
Martos L, Bonet E, Medina P, Navarro S, Zorio E, Rueda J, Aznar JA, Arnau MA, Osa AM, Estellés A, Bertina RM, España F. C0068 Haplotypes of the endothelial protein C receptor gene and circulating protein C levels. Thromb Res 2012. [DOI: 10.1016/j.thromres.2012.08.026] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
40
|
Martos L, Navarro S, Medina P, Bonet E, López-Fernández MF, Roldán V, Tássies D, Marco P, Alberca I, Corral J, Mira Y, Lecumberri R, Iruin G, Velasco F, Reverter JC, Ferrando F, Costa-Pinto MJ, Vayá A, Vicente V, Mauricio AG, González-Porras JR, Monteagudo J, Martínez-Marini T, Blanco ML, Aznar JA, Estellés A, España F. C0235 Identification of mutations in the protein C gene in a panel of 65 Spanish families with protein C deficiency. Thromb Res 2012. [DOI: 10.1016/j.thromres.2012.08.029] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
41
|
Bonet E, Medina P, Navarro S, Martos L, Estellés A, Bertina RM, España F. C0076 The endothelial protein C receptor is essential for protein C activation in vivo. Thromb Res 2012. [DOI: 10.1016/j.thromres.2012.08.028] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
42
|
Ramón LA, Braza-Boïls A, Gilabert J, Chirivella M, España F, Estellés A, Gilabert-Estellés J. microRNAs related to angiogenesis are dysregulated in endometrioid endometrial cancer. Hum Reprod 2012; 27:3036-45. [DOI: 10.1093/humrep/des292] [Citation(s) in RCA: 50] [Impact Index Per Article: 4.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/30/2022] Open
|
43
|
Gilabert-Estellés J, Ramón LA, Braza-Boïls A, Gilabert J, Chirivella M, España F, Estellés A. Plasminogen activator inhibitor-1 (PAI-1) 4 G/5 G polymorphism and endometrial cancer. Influence of PAI-1 polymorphism on tissue PAI-1 antigen and mRNA expression and tumor severity. Thromb Res 2012; 130:242-7. [DOI: 10.1016/j.thromres.2011.10.007] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/02/2011] [Revised: 09/16/2011] [Accepted: 10/10/2011] [Indexed: 01/08/2023]
|
44
|
Navarro S, Bonet E, Medina P, Martos L, Ricart JM, Vayá A, Todolí J, Fontcuberta J, Estellés A, España F. Haplotypes of the endothelial protein C receptor gene and Behçet's disease. Thromb Res 2012; 129:459-64. [DOI: 10.1016/j.thromres.2011.07.032] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/13/2011] [Revised: 07/14/2011] [Accepted: 07/15/2011] [Indexed: 11/25/2022]
|
45
|
Navarro S, Bonet E, Estellés A, Montes R, Hermida J, Martos L, España F, Medina P. The endothelial cell protein C receptor: Its role in thrombosis. Thromb Res 2011; 128:410-6. [DOI: 10.1016/j.thromres.2011.08.001] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/13/2011] [Revised: 07/14/2011] [Accepted: 08/01/2011] [Indexed: 12/01/2022]
|
46
|
Roldán V, Ordoñez A, Marín F, Zorio E, Soria JM, Miñano A, España F, González-Conejero R, Pineda J, Estellés A, Fontcuberta J, Vicente V, Corral J. Antithrombin Cambridge II (A384S) supports a role for antithrombin deficiency in arterial thrombosis. Thromb Haemost 2009; 101:483-486. [PMID: 19277409] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/27/2023]
Abstract
Although the control of thrombin in the microvasculature at the endothelial cell surface is crucial to prevent atherothrombosis, the role of antithrombin in arterial thrombosis is unclear. It is widely considered that antithrombin deficiency is unlikely to contribute to arterial thrombosis, but no convincing epidemiological study has been performed because of the low frequency of this deficiency. In this study we evaluated the role in myocardial infarction (MI) of a relatively common mutation affecting antithrombin gene (A384S: Antithrombin Cambridge II) that has functional features that may impair the right control of thrombogenic events caused by injury to the vascular wall. Moreover, this deficiency, which is not detected using common methods to diagnose antithrombin deficiency, also increases the risk of venous thrombosis. We included 1,224 patients with MI (691 consecutive patients and 533 survivors of a premature event), and 1,649 controls. The mutation was identified in 0.3% of controls, but 0.8% of MI patients. After adjusting for sex and other cardiovascular risk factors, the antithrombin Cambridge II significantly increased 5.66-fold the risk of MI (95% CI: 1.53-20.88; p = 0.009). Interestingly, young patients had the highest risk of MI associated with the mutation (OR: 9.98; 95%CI: 1.60-62.24; p = 0.009). This is the first epidemiological study that supports a role for antithrombin deficiency in arterial thrombosis. These results suggest that deficiency of antithrombin may be an independent risk factor for MI that has been underestimated, but larger studies are needed to confirm the relevance of inhibitors of thrombin in arterial thrombosis.
Collapse
Affiliation(s)
- Vanessa Roldán
- Centro Regional de Hemodonación, C/ Ronda de Garay s/n, Murcia 30002, Spain
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
47
|
Solá E, Vayá A, Villa P, España F, Estellés A, García K, Hernández-Mijares A. Obesity and Activated Protein C Resistance. Pathophysiol Haemos Thromb 2009; 36:64-8. [DOI: 10.1159/000173723] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Received: 04/14/2008] [Accepted: 07/21/2008] [Indexed: 11/19/2022]
|
48
|
Zorio E, Medina P, Rueda J, Millán JM, Arnau MA, Beneyto M, Marín F, Gimeno JR, Osca J, Salvador A, España F, Estellés A. Insights into the role of microRNAs in cardiac diseases: from biological signalling to therapeutic targets. Cardiovasc Hematol Agents Med Chem 2009; 7:82-90. [PMID: 19149547 DOI: 10.2174/187152509787047676] [Citation(s) in RCA: 36] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/27/2023]
Abstract
microRNAs have recently opened new pathways to explain gene expression and disease biology in many scenarios, including cardiac diseases. microRNAs are endogenous small non-coding RNAs that mediate post-transcriptional repression or messenger RNA degradation. By annealing to inexactly complementary sequences in the 3' untranslated region of the target messenger RNA, protein level is down-regulated. Several microRNAs appear to act cooperatively through multiple target sites in one gene and, conversely, most microRNAs can target several genes. miR-133 and miR-1 are specifically expressed in cardiac and skeletal muscle and control myogenesis, cardiac development, cardiac performance and cardiomyocyte hypertrophy (mainly by tuning transcription factors and other growth-related targets). They also modulate the expression of certain cardiac ion channels and related proteins with proarrhythmic effect. Besides them, other microRNAs have been shown to exert influence on the myocardial growth, the electrical balance and the angiogenesis processes that take place in the heart. Bioinformatics is a useful tool to identify potential targets of a given microRNA, although there is still substantial concern about their reliability. Experimental manipulation of microRNAs has provided a tantalizing basis to speculate that future research on microRNAs may yield important progress in the prevention of sudden cardiac death and in the treatment of cardiac heart failure. However, the final effect of the blockage of microRNAs in vivo remains unclear, since each of them can target hundreds of genes with different intensity. The era of the microRNAs in cardiovascular diseases has just started.
Collapse
Affiliation(s)
- E Zorio
- Cardiology Department, Hospital Universitario La Fe, Av. Campanar 21, Valencia, Spain.
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
49
|
Cosín R, Estellés J, Ramón L, España F, Gilabert J, Romeu A, Estellés A. O4 Vascular endothelial growth factor (VEGF) polymorphisms (−460C/T, +405G/C and 936C/T) and endometriosis. Their influence on VEGF expression. Thromb Res 2009. [DOI: 10.1016/s0049-3848(09)70029-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
50
|
Solá E, Navarro S, Medina P, Vayá A, Estellés A, Hernández-Mijares A, España F. Activated protein C levels in obesity and weight loss influence. Thromb Res 2008; 123:697-700. [PMID: 18834618 DOI: 10.1016/j.thromres.2008.07.017] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/07/2008] [Revised: 07/16/2008] [Accepted: 07/29/2008] [Indexed: 11/30/2022]
Abstract
Obesity is associated with a high risk of cardiovascular events. Several haemostatic disturbances which could contribute to this increased risk have been described in obesity; nevertheless, the state of coagulation inhibitors has been scarcely studied in these patients. The aim of the present study was to compare activated protein C levels in obese patients and in a control group, and to evaluate the effect of weight loss. In 67 severe or morbid obese patients, an evaluation was performed at baseline and 3 months after diet. The same determinations were performed in 67 healthy volunteers with normal body weight. We also quantified the levels of protein C and prothrombin fragment 1+2. Obese patients showed significantly higher levels of activated protein C, protein C and fragment 1+2. No correlation was found between activated protein C and fragment 1+2 levels in obese patients. After three months of diet, a significant decrease in activated protein C and fragment 1+2 was observed. In conclusion, activated protein C levels are increased in obese patients, but only a minor fraction of this increase may be explained by the higher thrombin generation and C protein levels. Activated protein C levels decrease with weight loss, due in part to a thrombin generation reduction.
Collapse
Affiliation(s)
- Eva Solá
- Endocrinology Service, Doctor Peset University Hospital, Valencia, Spain.
| | | | | | | | | | | | | |
Collapse
|